Beam Therapeutics Inc.

News that US Food and Drug Administration Center for Biologics Evaluation and Research (CBER) director Peter Marks submitted his resignation, effective 5 April, late in the day on 28 March shook the b

Cargo Therapeutics’ decision to end all development for its allogeneic cell therapy technology platform and its cancer cell therapy candidates is not the kind of news the biopharmaceutical sector need

Beam Therapeutics sees BEAM-302 as having potential for eventual accelerated approval from the US Food and Drug Administration in alpha-1 antitrypsin deficiency (AATD) after announcing positive early

This year’s American Society of Hematology (ASH) meeting delivered positive Phase II results for a new daily oral therapy and promising interim Phase I/II data for a one-time base editing treatment fo